Genetically, AITL is characterized by a number of genomic mutations in TET2, RHOA, DNMT3A, and IDH2 (Fiore et al., 2020a; Nakamoto-Matsubara et al., 2014; Odejide et al., 2014; Sakata-Yanagimoto et al., 2014; Yoo et al., 2014). This evidence concerns the gene RHOA and angioimmunoblastic T-cell lymphoma.